ResMed (RMD) Expected to Release Quarterly Earnings on Thursday

ResMed (NYSE:RMD) is anticipated to issue its Q1 2027 results after the market closes on Thursday, October 29th. Analysts expect the company to post earnings of $2.69 per share and revenue of $1.39 billion for the quarter. Interested persons may visit the company’s upcoming Q1 2027 earnings report page for the latest details on the call scheduled for Thursday, October 29, 2026 at 4:30 PM ET.

ResMed (NYSE:RMD) last released its quarterly earnings data on Thursday, August 6th. The medical equipment provider reported $2.95 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.89 by $0.06. The business had revenue of $1.46 billion during the quarter, compared to the consensus estimate of $1.46 billion. The business’s revenue was up 8.6% compared to the same quarter last year. During the same period last year, the company posted $2.55 earnings per share. On average, analysts expect ResMed to post $12.11 EPS for the current fiscal year and $13.19 EPS for the next fiscal year.

ResMed Stock Down 1.1%

RMD stock opened at $250.52 on Wednesday. The stock’s 50 day simple moving average is $230.81 and its 200 day simple moving average is $225.58. ResMed has a 12-month low of $180.26 and a 12-month high of $277.67.

ResMed Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, September 24th. Shareholders of record on Thursday, August 20th were issued a $0.66 dividend. This represents a $2.64 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date of this dividend was Thursday, August 20th. This is a positive change from ResMed’s previous quarterly dividend of $0.60.

Insider Transactions at ResMed

In related news, Director Peter Farrell sold 8,000 shares of ResMed stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $225.00, for a total value of $1,800,000.00. Following the completion of the sale, the director owned 52,773 shares of the company’s stock, valued at $11,873,925. The trade was a 13.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Michael Farrell sold 4,991 shares of ResMed stock in a transaction on Friday, August 7th. The stock was sold at an average price of $205.69, for a total value of $1,026,598.79. Following the completion of the sale, the chief executive officer directly owned 466,256 shares of the company’s stock, valued at $95,904,196.64. The trade was a 1.06% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 24,343 shares of company stock worth $5,396,098 in the last ninety days. Insiders own 0.58% of the company’s stock.

Wall Street Analyst Weigh In

RMD has been the topic of a number of research analyst reports. The Goldman Sachs Group reaffirmed a “buy” rating on shares of ResMed in a report on Wednesday, July 1st. Robert W. Baird set a $213.00 price objective on ResMed in a report on Friday, August 7th. KeyCorp lifted their price objective on ResMed from $255.00 to $267.00 and gave the stock an “overweight” rating in a report on Monday, August 31st. Royal Bank Of Canada raised ResMed from a “sector perform” rating to an “outperform” rating and boosted their target price for the stock from $244.00 to $262.00 in a research report on Tuesday, September 15th. Finally, Weiss Ratings upgraded shares of ResMed from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, October 8th. Seven investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat.com, ResMed presently has an average rating of “Hold” and an average price target of $243.23.

About ResMed

ResMed Inc is a medical equipment and software company that develops solutions for sleep-disordered breathing, respiratory conditions and other chronic diseases. The company is best known for its positive airway pressure (PAP) devices used to treat obstructive sleep apnea, along with masks, accessories and related patient support services.

ResMed also provides cloud-connected health technology, including remote-monitoring platforms and software used by healthcare providers, medical equipment suppliers and care organizations.